Clearstream Share Discussion Threads

[tole] 24/3/2006 18:35

Clearstream (Reduce, Closing Price £0.58)
Supply and distribution agreement announced.

Analyst: Ian Hunter
Clearstream, the developer and manufacturer of catheters, stents and stent delivery systems used in the angioplasty medical market, this morning announced that it has concluded a supply and distribution agreement for guidewires from an unnamed manufacturer. Guidewires are used to position stents in arteries, which in turn help open blocked vessels, improving blood flow. This agreement diversifies the range of guidewires the company can market under its own brand name. This is an incremental positive for the company as we await news on the development of its drug eluting stent. Any progress on the latter will have a marked effect on the company's future growth.

[currypasty] 23/3/2006 08:58

LONDON (AFX) - ClearStream Technologies Group PLC said it has expanded its
range of cardiovascular medical devices though an agreement to distibute
guidewires for angioplasty treatment

[currypasty] 23/3/2006 07:49

RNS Number:2414A
ClearStream Technologies Group PLC
23 March 2006

ClearStream Technologies Group plc



Announces New Supply and Distribution Agreement



23rd March 2006



ClearStream, a specialist supplier of cardio vascular medical devices, is
pleased to announce that it has concluded a supply and distribution agreement
for guidewires from an established OEM guidewire manufacturer. Under this
agreement ClearStream will supply coronary and peripheral guidewires under the
ClearStream brand for use in conjunction with its own and other angioplasty
devices. These guidewires have previously been CE Marked and it is expected that
ClearStream will commence shipment to the market under the ClearGuide trademark
in April 2006.



ClearStream CEO Andy Jones commented; "We are delighted to have concluded this
important agreement. The addition of these clinically proven guidewires is part
of our strategy to broaden our portfolio with complementary products, which will
not only increase revenues but also leverage additional sales of our existing
products. This is an ongoing strategy and negotiations are in hand to bring
further products under the ClearStream brand for sale through our established
distributor network".

[felix99] 07/3/2006 08:35

Well I bought a few Curry ! You got any forecasts for this thing?

[currypasty] 07/3/2006 08:31

Still moving up, must be some delayed trades in

[currypasty] 07/3/2006 07:49

RNS Number:3916Z
ClearStream Technologies Group PLC
07 March 2006


CLEARSTREAM TECHNOLOGIES GROUP plc TRADING UPDATE
Sales and orders received for own-brand products increased significantly in
first half;
Full year sales now likely to be substantially ahead of earlier market
expectations;
#3.0 m (Euro4.4 m) Placing approved at EGM


ClearStream Technologies Group plc ("ClearStream" or "the Company"), the
innovative developer and manufacturer of medical devices, in particular
catheters, stents and stent delivery systems that are used in the rapidly
growing interventional, angioplasty medical market, announces the following
update on trading.

For the six months ended 31 January 2006 there has been a significant increase
in the level of sales made and orders received in respect of the Company's own
brand products, especially the Company's low injury bare metal stent, the
ClearFlex, and its high performance catheters, the Nimbus(R) Pico and LitePACTM.
The Company has noted that this advance in sales had been primarily in the last
three months of the period and initial indications are that this pattern is
continuing into the second half of the financial year, ending 31st July 2006. As
a result, the Company now anticipates that sales for the full year are likely to
be significantly ahead of earlier market expectations.

The increased demand has arisen through a combination of higher sales by a
number of ClearStream's established distributors and by orders from a number of
new distributors. Additionally, the market for stent delivery catheters sold on
a business-to-business basis appears to be showing a marked recovery.

The total number of Company distributors rose from 20 to 29 during the financial
period and it is likely that this number will increase further during the
remainder of the current year. This reflects the growing recognition within the
market of the excellent clinical performance and strength of reputation of
ClearStream's established product offerings, in particular the outstanding
performance and low restenosis levels associated with the ClearFlex as
increasingly evidenced by clinical data. The growth in distributors also
reflects the anticipated launch of the new ClearStream drug eluting stent, the
Intrepide.

The Intrepide, which has already concluded human clinical trials, will commence
sales into certain non-CE Mark markets in March 2006. ClearStream has already
received initial orders for supply of the product from a number of distributors.
Preparation activity for the submission for the CE registration of the Intrepide
is now in a very advanced state and is expected to be submitted for approval in
the next two weeks.

The worldwide market for such stents is estimated to be around $5 billion per
annum and is currently served by few providers. The Directors believe that, with
clear product differentiation, ClearStream can capture a share of this market
which would be significant in terms of sales for a company of ClearStream's
size. Additionally the Directors confirm that the Company is seeking to widen
the portfolio of products it offers clients through third party distribution
agreements and anticipates making further announcements shortly on these
arrangements.

Whilst further growth in sales is anticipated during the second half of the
financial year, margins will remain tight until the Company is able to build
market share for the Intrepide.

At the EGM held yesterday, the placing arrangements to raise a further Euro4.4m
were formally approved by shareholders concluding the successful fundraising
for the business. The proceeds of the Placing will be utilised:


* to continue the development of ClearStream's next generation DES product.

* to fund further investment in the Company's sales and marketing
capability;

* to provide working capital to take advantage of the opportunities
afforded by the Intrepide and to fund the CE Marking of this product,

* to provide additional working capital and manufacturing capacity to
support the increased level of sales being experienced in ClearStream's
existing own brand products.

Chairman, Mike Love, commented "with the launch of the Intrepide, ClearStream
has a high performance product, with which to address the rapidly expanding DES
market. ClearStream has also made significant progress in reversing the
underperformance of business to business (OEM) sales for its catheter products.
Additional new product launches and signings, which are already in the pipeline,
will further re-enforce this progress".

The interim results for the six months ended 31 January 2006 will be announced
on 30th March 2006.

[currypasty] 10/2/2006 15:08

RNS Number:2608Y
ClearStream Technologies Group PLC
10 February 2006




CLEARSTREAM TECHNOLOGIES GROUP PLC

CONDITIONAL PLACING AND TRADING UPDATE



Highlights



* Placing of 6,120,000 shares at 49 pence per share to raise
approximately #3 million

* EGM to approve Placing on 6 March 2006

* Proceeds to be applied to

- continue the development of ClearStream's own next generation DES
product

- fund further investment in Company's sales and marketing capability

- to provide working capital to exploit the new DES offering, the
Intrepide

- to provide working capital and manufacturing capacity to support
increasing sales

* Trading for six months to 31 January 2006 expected to be in line
with market expectations

* Significant increase in sales since end of quarter 1,
particularly own brand sales

* Sales for year ending 31 July 2006 now expected to be
significantly ahead of market expectations

[currypasty] 28/12/2005 09:51

RNS Number:2181W
ClearStream Technologies Group PLC
28 December 2005




ClearStream Technologies Group plc is pleased to announce that it has concluded
a regulatory and supply agreement with a US-based medical device R&D company for
the exclusive supply of a drug eluting stent (DES) into all territories world
wide, with the exception of the USA and Canada. This new stent will be
incorporated with one of ClearStream's high performance stent delivery catheters
to create a new DES product offering. This product, which has already concluded
human clinical trials, will be launched into certain markets in January and
ClearStream is pleased to announce that it has already booked orders for supply
of the product. This agreement and the advanced state of regulatory readiness of
the product will also enable the company to accelerate its plans to apply for a
CE Mark allowing sales throughout its distribution network, including mainland
Europe.

[currypasty] 17/10/2005 08:30

RNS Number:7177S
ClearStream Technologies Group PLC
17 October 2005



ClearStream Technologies Group plc announces that it has completed a placing of
1,434,869 new ordinary shares at 48 pence per share to raise #688,737 before
expenses. The funds will be used to provide additional working capital.



Directors of the Company took part in the Placing as follows:


No. shares taken as Total no. shares % of enlarged share
part of the placing now held capital
Mike Love, Non-Executive 354,166 354,166 1.99
Andy Jones, Chief Executive 212,500 1,467,144 8.25
Pauline Oakes, Supply Chain Director 7,083 115,653 0.65



In addition, Tom Delaney, Company Secretary and Chief Financial Officer, took
8,500 shares as part of the placing.





Directors stump up £280k !!!!

[currypasty] 04/10/2005 15:41

RNS Number:1905S
ClearStream Technologies Group PLC
04 October 2005


CLEARSTREAM TECHNOLOGIES GROUP PLC
ANNOUNCEMENT OF PRELIMINARY RESULTS FOR THE YEAR ENDED 31 JULY 2005


Results in line with Market Expectations for year to 31 July 2005

ClearStream Technologies Group plc ('ClearStream') announces its preliminary
audited results for the year ended 31 July 2005. Quoted on AIM (stock code:
CTN). ClearStream is headquartered in Enniscorthy, Ireland and is a specialist
supplier of medical devices used in the rapidly growing interventional medical
market.


KEY POINTS:

* Company successfully floats on Alternative Investment Market in November
2004

* Circa Euro7.0m of new finance raised through AIM flotation

* 3 new interventional products launched; the ClearFlex(R)-X, the Nimbus(R)
Pico and the LitePACTM

* Continued good progress on DES project with improved market opportunity for
new product

* International distributor network strengthened and expanded

* ClearStream brand sales ahead of expectations with second half revenues
twice as high as in the first half.

* Growth in ClearStream brand sales continuing into 2006

* Renewed growth in OEM markets now anticipated following disappointing
growth in 2005

* Sustained drive to improve yields, reduce material costs and generally
improve efficiencies.

* Trading results in line with expectations


2005 2004

Revenues Euro2.65M Euro4.2M
Loss before tax and goodwill Euro4.4M Euro3.1M
Loss before tax (after R&D expenditure of Euro1.5m (2004:Euro1.3m) Euro4.5M Euro3.2M
Loss per share euro Euro0.34 Euro0.66
Cash Position at year end Euro0.25M Euro0.0M



On outlook, Chairman, Frank Traynor said:

"Going forward, the Board's attention will be focused on expanding the
ClearStream business, moving first to operational profitability and then driving
for further profitable growth. We anticipate further good progress in 2006".

[currypasty] 19/7/2005 07:48

RNS Number:0142P
ClearStream Technologies Group PLC
19 July 2005

ClearStream Technologies makes significant progress
towards launch of its Drug Eluting Stent


ClearStream Technologies plc is pleased to announce that it has concluded
Collaboration and Supply Agreements with its partner to develop and supply
polymer coating technology and equipment to coat its ClearFlex bare metal stent
as a drug eluting stent (DES). These agreements formalise arrangements
previously covered by a Memorandum of Understanding between the companies.



Recently published data from a registry in Israel indicated that ClearStream's
ClearFlex bare metal stent has a restenosis performance of just 5% over 6 months
clinical follow up, in a normally distributed population of patients.
ClearStream believes that this makes the ClearFlex an ideal base for a
potentially superior DES. The polymer to be used features a bi-layer system
with a biodegradable layer containing the drug, thus avoiding the concerns
inherent in non-biodegradable systems, such as those DES currently on the
market, which retain a significant percentage of un-eluted drug in the long
term.



The in-vivo trials continue to schedule and ClearStream expects to conclude its
development programme and commence CE Marking clinical trials of its DES
offering to plan in early 2006.



While the development of the Company's DES offering is progressing well and
ClearStream's own branded product sales volumes continue to grow, OEM sales, as
indicated in the interim statement, continue to be slower than expected. The
position reported then has been exacerbated by the difficulties certain
customers or potential customers are having with patent litigation action being
taken against them which is stalling their own DES product releases. These
patent issues are not expected to affect ClearStream's own DES offering because
of the technology and drug used and this may indeed enhance the opportunity for
its own brand product.



The effect of the OEM slowing is that sales for the year will be lower than
expected. However, the substantial measures that have already been taken to
reduce costs mean that that losses for the year should only be slightly in
excess of market expectations.



Nevertheless, ClearStream anticipates signing a number of new OEM agreements in
the near future and to make further progress in developing this channel to
market for its products.



The Company is pleased to confirm that Tom Delaney has taken up the post of CFO
since June 1st. Also in preparation for the release of its DES product,
ClearStream has taken steps to strengthen its Sales and Marketing team, with the
appointment of a new Marketing Manager and UK Sales Manager.

[currypasty] 14/4/2005 08:01

RNS Number:0307L
ClearStream Technologies Group PLC
14 April 2005


ClearStream Technologies Group plc

Interim Results for the six months ended 31st January 2005


ClearStream Technologies Group plc ("ClearStream") announces its unaudited
results for the six months ended 31st January 2005. ClearStream is based in
Enniscorthy, Co. Wexford, Ireland and is a supplier of interventional medical
devices for use in Coronary and Peripheral arteries.

Key Points

* Total revenue was Euro1.39M (2004: Euro2.42M)
* Trading losses were Euro1.28M (2004: Euro0.44M)
* After R&D, depreciation, net interest and goodwill charges the final loss
for the period was Euro2.03M. (2004: Euro1.24M)
* Trading losses in line with expectations, following strict cost control
* Significant improvement in performance anticipated in second half
* Strengthened position in emerging Asian markets
* Pace of introduction of drug eluting stents by OEM customers lags
expectations
* Continuing good progress in the development of the ClearStream own brand
drug eluting stent (DES)
* ClearStream brand bare metal stent sales volumes continue to increase
* Positive evaluations for new products released during the period
* Upward trend in order intake for own brand and OEM products

ClearStream is a manufacturer of interventional medical devices primarily used
for coronary and peripheral angioplasty and stenting procedures. ClearStream
operates two channels to market, sales of ClearStream branded devices sold
through distributors and sales of unbranded devices on an OEM basis to other
medical device companies for use as angioplasty catheters or as stent delivery
systems.

Results Overview

The Directors present their interim report for the six months to January 31st
2005. This is the first report since flotation on AIM on November 11th 2004.
Although total revenues for the first half are below expectations, the losses
for the period are in line and sales volumes of ClearStream branded devices
continue to grow as planned.

In this context, the results for the period are satisfactory with substantive
progress being made.

In the coronary market, sales of delivery systems to OEM customers are showing a
positive trend. In a significant development, ClearStream received its first
major order to supply catheters to an OEM customer in the Asian market for use
as a drug eluting stent delivery system. In addition to this breakthrough we
have high expectations of making additional progress on supplying, on an OEM
basis, delivery systems to other customers serving the drug eluting market.

The general market for coronary stents continues to be dominated by the DES,
which continues to increase its market share at the expense of the more
traditional bare metal stent.

Sales in the first half of 2004 reflected this retrenchment in the bare metal
stent market. Although sales in the first half of 2005 are lower than sales in
the first half of 2004, they now reflect an upturn in sales based on new
products relating to the DES market. Compared with earlier expectations, this
upturn has been slower than expected, due to delays in potential customers
completing their regulatory market approvals. We believe some of these approvals
are now close to completion.

Not withstanding the general trend, ClearStream continues to receive orders from
OEM customers for delivery systems for use with non-drug eluting stents. For
example, in January, an order was received worth Euro1M over 6 months for stent
delivery catheters from an existing OEM customer in Europe.

While progress has been made, OEM sales have built more slowly than expected.
This has been largely due to delays in customers bringing their own new drug
eluting stents to market. In particular, we have experienced delayed order
draw-down from one contracted customer and a slower than expected take on of new
OEM customers. This is regarded as a timing issue and is not expected to
adversely affect ClearStream in the longer term.

ClearStream's own bare metal stent, the ClearFlex, continues to gain market
share with increased customer volumes sold, despite the continued decline of the
bare metal stent market experienced by our competitors and OEMs.

There continues, however, to be severe margin pressure in this market segment,
which has been further exacerbated by the significant change in the US dollar
exchange rate. There is growing evidence from clinical usage that the ClearFlex
stent is capable of achieving clinical performance levels that are almost
comparable with those of the more expensive drug eluting products. Consequently,
we continue to believe that ClearFlex can continue to increase its market share
in the residual bare metal stent market.

The Company continues to have success in the recruitment of new distributors.
Contracts have now been signed with distributors in Italy and Switzerland and
discussion with a distributor in Holland are at an advanced stage.

DRUG ELUTING STENT (DES) Project

This remains the main focus of our investment plans and represented the largest
application of the funds raised for product development during the flotation.
The project continues to make good progress. Feasibility studies have been
completed, proving the technology and the proposed manufacturing process.
Preliminary in vivo trials have commenced with the first production versions of
the product. This is a very important and significant milestone achieved to
schedule.

The emerging evidence of the superior clinical performance of the ClearFlex
stent, further strengthens our belief that, when combined with drug eluting
capability, the ClearFlex has the potential to offer superior clinical
performance to currently available drug eluting stents.

New Product Introductions

During the period, the Company released 3 new interventional products; two
Coronary, the ClearFlex(R)-X and the Nimbus(R) Pico, and one Peripheral, the
LitePAC(TM). These products are sold under the ClearStream brand.

The ClearFlex(R)-X is a bare metal coronary stent system and the Nimbus(R) Pico
is a PTCA catheter. Both feature ClearStream's new innovative XXtraFlex(TM)
transition technology. XXtraFlex(TM) transition is a major development in the
design of the transition portion of the catheter. It combines pushability and
flexibility in a manner, which focuses forces in a forward direction ensuring
smooth pushability and significantly improves access to lesions in coronary
arteries.

The LitePAC(TM) is a PTA catheter for use in peripheral vessels. The LitePAC(TM)
is an innovative catheter, which employs technology similar to that used in
coronary catheters. A number of LitePAC(TM) catheters have been very
successfully evaluated as catheters employed as part of carotid stenting
procedures.

Elsewhere, a technical difficulty with the planned peripheral stent project has
led to a delay in the release of this product. Potential solutions to this
specific difficulty have been identified and are currently under detailed
investigation.

Despite encouraging sales of ClearStream branded products, the new product
introductions, to some extent, slowed sales as distributors were reducing stock
levels of the old products while new product evaluations were being conducted.
In some countries, registrations had to be updated prior to replenishing stock
levels with the new products. In all cases, evaluations have gone well for all
three products.

Financial results

Sales for the period were Euro1.39M; comprising Euro0.44M for own branded products,
Euro0.58M for OEM and Euro0.38M for other sales. After sales expenses of Euro0.32M and
general and administration expenses of Euro0.52M, the Company recorded a trading
loss of Euro1.28M. After R&D costs of Euro0.53M, depreciation, net interest and
goodwill charges the loss for the period was Euro2.03M.

The net cash outflow for operating activities in the period was Euro2.84M of which
approximately Euro1.75M related to underlying trading. The cash outflow from term
banking facilities was Euro0.94. Including the funds received from the flotation,
net cash at the end of the period was Euro2.4M.

Staff and Management

The Board would like to thank all of the staff of ClearStream for their
continued support and efforts across a very challenging period. Without their
continued dedication and effort we would not be able to realise our ambitious
plans for the future.

There have been a number of significant appointments and changes to the
management team at ClearStream.

Gabrielle Gahan, who has served as Finance Director for the past 5 years, has
resigned with effect from June 2005 to pursue a change of career outside of her
current profession and away from this industry. The Board would like to thank
Gabrielle for her strong contribution and wish her success. A successor to
Gabrielle, Thomas Delaney, has been appointed and will take up the position of
Chief Finance Officer on June 1st 2005.

The Company is also pleased to announce the appointment of Dermot Keena as
Product Development Manager and the Board wishes him every success in this
position.

Outlook

ClearStream now has significant business in China, India and the Middle East and
will continue to focus on increasing its market penetration in other countries
in Asia, in addition to its business in the rest of the World.

Based on current order intake and trading patterns, we anticipate that there
will be a sustained improvement in sales of both OEM and ClearStream branded
products in the second half of the year. This belief is based on the expectation
of a good take up of the newly released coronary and peripheral products and on
an expected order growth from the new distributors in Italy, Switzerland and
potentially Holland.

A number of product enhancements and range extensions will be released during
the second half, further enhancing ClearStream's competitive position.

We expect a significant improvement in the second half performance and although
sales are likely to be below earlier estimates, we anticipate losses are likely
to be similar to the first half, despite the fact that R&D spend will more than
double to over Euro1M in the second period. The Board's focus on careful cost
control will continue.

[shedjock] 11/3/2005 11:06

I've emailed the company asking for clarification

[currypasty] 11/3/2005 11:05

yes, i wondered about that, you would think the LSE would double check the ticker was completely redundant before re-allocating it.

[currypasty] 11/3/2005 09:57

wassup today then ?

[currypasty] 15/2/2005 08:21

RNS Number:5946I
ClearStream Technologies Group PLC
15 February 2005


Trading update and notification of reporting date


ClearStream will release its interim results for the six months ended 31 January
2005 on 14 April 2005.


Earnings for the period are expected to be in line with expectations and sales
of ClearStream branded devices continue to be buoyant and in line with forecast.


In a significant new development, ClearStream has received its first major order
to supply catheters to an OEM customer in the Asian market for use as drug
eluting stent delivery systems. This order represents a further breakthrough
into the Asian market. ClearStream now has significant business in China and
India and will continue to focus on increasing its penetration in other
countries in Asia, in addition to its business in the rest of the World.


In a further development, ClearStream has received orders worth Euro1M over the
next 6 months for stent delivery catheters from an existing OEM customer.


Elsewhere, OEM sales are somewhat slower than expected due to delayed order draw
down from one contracted customer and a slower than expected take on of new OEM
customers. This has been largely due to delays in these customers bringing their
own drug eluting stents to market. This is regarded as a timing issue and is
not expected to adversely impact ClearStream in the longer term.

[unionhall] 25/1/2005 11:54

Up the rebels !!

Do either of you locals have inside knowledge on real expected revenue ?

(sister has house in Fethard-on-Sea - can I join the club ??)

[currypasty] 24/1/2005 11:28

Company ClearStream Technologies Group PLC
TIDM CTN
Headline Product Launch
Released 11:16 24-Jan-05
Number 7041H



ClearStream Technologies Group plc, the developer, manufacturer and supplier of medical devices, is pleased to announce the release of three new interventional products, two Coronary and one Peripheral. These products will be sold under the ClearStream brand and are now available commercially.



The Coronary products are the new Nimbus® Pico PTCA catheter and the ClearFlex®-X coronary stent system. Both feature ClearStream's new innovative XXtraFlex™ transition technology.



XXtraFlex™ transition is a major innovation in transition design. It combines pushability and flexibility in a manner, which focuses forces in a forward direction ensuring smooth pushability and facilitates significantly improved access to more distal lesions.



The LitePAC™ is a rapid exchange PTA catheter for use in peripheral vessels. The LitePAC™ is 0.014'' compatible and may be used in conjunction with 0.014'' distal protection devices. In a format similar to that for coronary catheters, the LitePAC™ has an overall length of 135cm and features 2.1F hypotube and 25cm long flexible distal portion. Balloon sizes range from 3.0mm x 15mm up to 7.0mm x 60mm.



For further information visit

[currypasty] 24/1/2005 11:25

news... but afn not showing it

[currypasty] 11/1/2005 10:35

2 Months since AIM list, due some news / press / action ... something !!!!

[tamaybroke] 20/11/2004 12:03

My sympathy,and that accent would pierce your skull.
Will keep ye informed of anything i hear.

[pilsner] 20/11/2004 11:24

No afraid not - Live in London - had to watch game in pub full of cork men.
Dont know much about these guys - heard an interview on the radio one day and said I would follow it for a while.